NPPB and pulmonary arterial hypertension: Assessment tests such as the New York Heart Association (NYHA) Functional Classification and the 6 minute walk distance (6MWD) and biomarkers such as brain natriuretic peptide (BNP), though helpful, are limited in their ability to show PAH disease progression or quiescence.